

M MALAGHAN
INSTITUTE
OF MEDICAL RESEARCH

Annual Report 2020

Contents

About us	2
Chairman's report	4
Director's report	5
Cancer	6
Infectious disease	8
Asthma & allergy	10
Gut health	12
Brain health	14
Technology	16
Principal Investigators	18
Publications	20
Financial overview	22
Philanthropic highlights	24
Funding	26
Trust board	28
Te Urungi Māori	32
Staff directory	34

INSIDE COVER IMAGE

Distant, together.

While the 2020 global COVID-19 pandemic changed the face of the Malaghan Institute, it did not dampen our spirit of scientific endeavour, nor the desire to work together to develop cutting-edge treatments and therapies for disease.

FRONT COVER IMAGE


CAR T-cells in action.

Pink CAR T-cells, manufactured at the Malaghan Institute, are shown attacking a clump of green blood cancer cells. As the cancer cells die they turn blue.



Year in review

OUR PEOPLE



7 PRINCIPAL INVESTIGATORS

15 RESEARCH FELLOWS

TE URUNGI
MĀORI ADVISORY
COMMITTEE
FORMED



VACCINE ALLIANCE
AOTEAROA NEW ZEALAND
- OHU KAUPARE HUAKETO
ESTABLISHED

RESEARCH

45 SCIENTIFIC PUBLICATIONS

THERAPEUTIC HOOKWORM
CLINICAL STUDY

\$8m CONTESTABLE
GOVERNMENT
FUNDING

ENABLE
CAR T-CELL
CLINICAL TRIAL

KEY INTERNATIONAL COLLABORATIONS

CHINA
ENGLAND
USA
AUSTRALIA
ISRAEL


CZECH
REPUBLIC
JAPAN
SINGAPORE



PHILANTHROPY

16 STRATEGIC PARTNERS

SUPPORTERS



9 RESEARCH PARTNERS

8 CHARITY OF CHOICE PARTNERS

\$6.26m
PHILANTHROPIC REVENUE

39%
OF TOTAL
FUNDING

About us

The Malaghan Institute is New Zealand's world-leading independent biomedical research institute with a focus on breakthrough discoveries in immunology and immunotherapy.

Our journey started more than 50 years ago with a vision to improve the lives of all New Zealanders. In 1966, a group of far-sighted New Zealanders set a course for world-class independent medical research to be carried out in Wellington. In 1986 the organisation was renamed the Malaghan Institute of Medical Research in recognition of the generosity of Tip Top founder Len Malaghan and his wife Ann, whose donation of shares from the company seeded the Institute.

Today, our cutting-edge research and clinical trials are advancing understanding of the immune system and its relationship to human health. With a world-class technology platform to deeply interrogate these relationships, leading scientists and worldwide collaborations, we are leveraging new knowledge to find better treatments and cures for disease and create economic opportunities for New Zealand.

Independent research

Our value to New Zealand lies in our independent status as a research organisation, backed by the community. As a registered charity, we are owned by New Zealand, for the benefit of all.


Through a range of funding sources, including philanthropic, government and corporate, the Malaghan Institute has developed the capability and expertise to deliver significant health and economic benefits to New Zealand, while retaining the freedom, flexibility and spirit to make breakthrough discoveries.

From benchtop to bedside

World-class immunological research and clinical trials come together on a single site at the Malaghan Institute. This pioneering approach enables scientists and doctors to work side by side, making new discoveries in the laboratory, translating them into new treatment options, and testing them in the clinic.




Key areas of research and discovery



CANCER

including blood, skin, brain, breast and colon.



INFECTIOUS DISEASE

including COVID-19, parasitic disease, malaria, hepatitis B and influenza.




ASTHMA AND ALLERGY

including eczema, allergic sensitisation, food allergy and autoimmunity.



GUT HEALTH

including hookworm therapy, metabolic disease, microbiome research, gut inflammation and nutrition.



BRAIN HEALTH

including multiple sclerosis and neurodegenerative brain disease.

Chairman's report



The Institute is the sum of many parts working together. First and foremost, our people. They are the real assets of the Institute. From laboratory staff, technicians, to IT, accounting and advocacy, their expertise, commitment and energy combine to deliver a powerful independent resource for New Zealand. They are led by two very astute executives, Director Professor Graham Le Gros and General Manager Mike Zablocki, who provide a seamless roadmap for success.

The Institute can achieve little without the necessary fuel; money. This is why the people across New Zealand who donate to the Institute, often several times a year over many years, are so important to us. As are the Trusts, the Foundations and organisations that identify and align themselves with our core values and intentions. And we should not forget our fellow Kiwis overseas who give generously. This exemplary support from across the community continues to be a great motivator to staff and trustees.

Contestable government support, namely through the Health Research Council of New Zealand's Independent Research Organisation fund, continues to be a core source of funding that has seen the performance of the Institute grow in leaps and bounds.

Again this year Trustees have given generously of their time and knowledge. They receive no reward other than in sharing the success and progress made by the researchers. Changes at the end of the year include the retirement of long-serving trustee Dan Williams, who has ably chaired our Audit and Risk Committee along with our Investment Committee. These roles will be taken up by our newest trustees Tony Mossman and Sir Paul Collins, respectively.

The Institute has also established the role of Distinguished Trustee (Retired), to acknowledge the contribution and continuing support given by retired trustees. This year Bryan Johnson and David Mossman will be so acknowledged.

Special mention has to be made of the Institute, the Director and his team from Otago and Victoria Universities being appointed by the Government as the leaders of a project to discover, evaluate and ensure New Zealand has a vaccine to tackle COVID-19. This is significant recognition of the leadership and knowledge of our team, and comes with heavy responsibilities to our community.

As Chairman, I can say this has been one of our busier years, with many challenges across the activities of the Institute. However, at no time have I been concerned about the wider team's ability to rise to the occasion and move forward with clear focus on what has to be achieved.

A handwritten signature in black ink, appearing to read 'G. Malaghan'.

Mr Graham Malaghan | CHAIRMAN
ONZM Hon DSc FCILT

Director's report



I want to thank our many supporters for their backing during what has been a very difficult year for everyone. As I've said before, COVID-19 has shown us just how dynamic and destructive a new infectious agent can be to humankind and how vital health research is globally.

Never has there been more pressure on scientists, scrutiny of our expertise or expectation to deliver. In saying that, the New Zealand scientific community has risen to the challenge superbly, and it has been fantastic to see the collaboration and solidarity across academic and independent research organisations, industry and government.

Vaccine Alliance Aotearoa New Zealand – Ohu Kaupare Huaketo, is tasked with helping secure a COVID-19 vaccine for New Zealand, working with local and international scientists to support the development of potential vaccine candidates. I am proud as Programme Director to help lead this national effort, a tremendous responsibility. I am buoyed by the immense expertise within the team, and the community of support around us. Of particular note, I would like to acknowledge the Hugh Green Foundation and an anonymous donor whose significant support have helped accelerate development of local vaccine candidates.

Despite all the disruption and uncertainty of recent months, credit goes to our scientific programmes for not skipping a beat and continuing to deliver quality, high-impact research in immunology and immunotherapy. Our gut health and cancer teams continue their important work on clinical trials, the ENABLE CAR T-cell clinical trial and the hookworm therapy clinical study, respectively. These are just two examples of community-driven research continuing to move forward in challenging times and having an impact on the lives of New Zealanders.

COVID-19 has laid bare the importance of effective communication between the scientific community and the public. Our Development and Communications team has risen to the challenge, informing and working with not just our supporters, but the media, ensuring the Malaghan Institute remains an effective and reliable voice in a tumultuous time where misinformation and uncertainty is rife.

Lastly, I would like to wholeheartedly thank our departing Head of Development Jenny Sim, after eight and a half years at the Institute. In her time here, Jenny has forged an authentic and powerful bond between our supporters and our research scientists. The high-level of community engagement we are fortunate enough to enjoy is no accident, and Jenny has been instrumental in creating an environment where this has been possible.

Once again, I would like to thank all supporters for helping ensure the Malaghan Institute remains at the forefront of biomedical research for New Zealand.

Professor Graham Le Gros | DIRECTOR
CNZM, FRSNZ, FRCPA(Hon)
BSc, Dip Immunol, MPhil, PhD

Cancer

Harnessing the power of the immune system to treat cancer continues to be the core area of research at the Malaghan Institute.

Through assisting the immune system to better recognise and respond to cancer cells in the body, our aim is to create gentler, more effective cancer treatments.

CAR T-CELL THERAPY

By reprogramming a patient's own immune cells to identify and kill cancer, CAR T-cell therapy is rapidly changing the face of cancer treatment globally. Already approved for use in several overseas jurisdictions, New Zealand's first CAR T-cell trial got underway at the end of 2019 through the joint venture between the Malaghan Institute and Wellington Zhaotai Therapies.

ENABLE CAR T-cell clinical trial

The ENABLE phase I dose escalation safety trial aims to treat certain types of relapsed and refractory B-cell non-Hodgkin lymphoma in patients who have exhausted other treatment options. Having gained the necessary regulatory approvals in the previous financial year, the phase I ENABLE trial has begun administering CAR T-cells to its first cohort of patients.

- The clinical team has since refined techniques to improve the CAR T-cell manufacturing process and to account for the differences between healthy donor and patient cells and improve the conversion of CAR T-cells.
- During the March–May 2020 COVID-19 lockdown period, patient referral and recruitment was put on temporary hold. It has since recommenced.
- Clinical Director Dr Robert Weinkove, together with colleagues in New Zealand and Australia, developed clinical guidelines for managing haematology and oncology patients during the pandemic.

Freemasons CAR T-cell Research Programme

In parallel to the ENABLE trial, the Freemasons CAR T-cell Research Programme aims to develop this technology further to both improve its efficacy and extend it to other forms of cancer. In January 2020, immunologist Dr Rachel Perret returned to the Institute to lead the programme, bringing her expertise in developing T-cell therapies, most recently at the Fred Hutchinson Cancer Research Center in Seattle, USA.



HYPOXIA-ACTIVATED DRUGS

PhD student Regan Fu completed his doctoral thesis assessing immunotherapies in combination with the hypoxia-activated drug tarloxotinib. Through adding a hypoxic trigger that activates in the oxygen-poor intratumoral environments, higher doses of chemotherapeutic or immunotherapeutic drugs can be delivered, without adversely affecting surrounding tissues. Future work is planned to better understand how tarloxotinib interacts with the immune system with a view to move towards potential clinical trials.

MITOCHONDRIA TRANSFER

With support from a Health Research Council of New Zealand (HRC) grant, further research is underway to better understand how and why mitochondria transfer between cells, especially in a cancer biology setting, where this plays a role in cancer survivability.

Tumour biology

The relationship between tumour biology and mitochondrial transfer in different cancer settings continues to be an important area of investigation. The cancer cell biology team is taking a molecular approach to this topic, and looking at the role of ATP production in mitochondrial transfer for tumours and metastases.

Transfer in bone marrow

Three different preclinical models of mitochondrial transfer in bone marrow have been developed by PhD student Georgia Carson, showing clear transfer using genetic markers from donor cells and the recipients' cells. Further work is being done to determine whether these healthy mitochondria are being exchanged with damaged mitochondria from the recipient, or donated wholesale.

GLIOBLASTOMA

BCL6, a molecule expressed in certain immune cells, remains a key molecule of interest in investigating what makes the brain cancer glioblastoma such an aggressive and persistent cancer. While BCL6 is an important molecule for a functioning immune system, its unexpected presence in glioblastoma cells indicates that it has a role in the disease. The cancer cell survival team is investigating whether the BCL6 found in glioblastoma cells is the same BCL6 found in immune cells, and whether blocking its expression can decrease the survivability of these tumours.



MIDDLE IMAGE: 'Keep Your Friends Close and Your Enemies Closer' – PhD student Rebecca Dawson

Bone derived cells (red) reaching an arm out to two clusters of distressed Rho O cells that lack mitochondria. Is this an act of friendship, or cannibalism? That's what the cancer cell biology group is trying to find out, with the image offering a tantalising insight into the elusive process of mitochondrial transfer, where healthy cells donate mitochondria to damaged ones. It's a common mechanism many cancers use to 'bounce back' from treatment, so understanding this process further is key to finding new kinds of cancer therapies.

Infectious disease



The COVID-19 global pandemic has brought the Institute's expertise and track record of harnessing the immune system to combat infectious diseases into national focus.

COVID-19

In response to the global COVID-19 pandemic, the Malaghan Institute was among leading scientists strongly advocating for a national vaccine strategy. In May 2020, the Government announced an initial \$37 million COVID-19 Vaccine Strategy, allocating \$10 million to support New Zealand researchers.

Vaccine Alliance Aotearoa New Zealand – Ohu Kaupare Huaketo

This partnership between the Malaghan Institute, the University of Otago and Victoria University of Wellington, has been tasked with establishing a national COVID-19 vaccine evaluation and development platform to screen, trial and accelerate the development of potential domestic and international COVID-19 vaccines. The programme has been boosted by donations to the Malaghan Institute, including from the Hugh Green Foundation. As well as supporting the platform, this is accelerating research and development of several local vaccine candidates.



IMAGE: Malaghan Institute Director Prof Graham Le Gros, Rt. Hon Jacinda Ardern, Prime Minister of New Zealand and University of Otago Assoc Prof. James Ussher. © Image Services, Victoria University of Wellington

COVID-19 vaccine candidate development

With collaborators, the Malaghan Institute is involved in the development of three local vaccine candidates:

- A recombinant spike protein vaccine in development at Victoria University of Wellington.
- An inactivated virus vaccine in development at the University of Otago.
- A pan-coronavirus vaccine being explored by Avalia Immunotherapies with international collaborators.

Given overseas frontrunners in the vaccine race, these vaccine candidates are being developed as 'second generation' vaccines that potentially offer longer-term immunity or could be used in specific patient populations such as the compromised or elderly. Dr Lisa Connor and her team are working alongside Professor Ian Hermans and the cancer immunotherapy team, testing these vaccine candidates for their ability to stimulate neutralising antibodies against the virus – indicators of an effective vaccine.

Dr Frances Priddy

Dr Frances Priddy, former Chief Medical Officer and Vice President of Clinical Development at the International AIDS Vaccine Initiative in New York, joined the Malaghan Institute's COVID-19 vaccine programme in late July. Dr Priddy brings a wealth of expertise and experience in infectious diseases and clinical trials and important international connections that will help boost New Zealand's COVID-19 vaccine efforts.

MALARIA VACCINE IN EARLY DEVELOPMENT

A trans-Tasman collaboration with the Ferrier Research Institute, the University of Melbourne and Avalia Immunotherapies has laid the groundwork for a novel malaria vaccine. Still in exploratory development, the project aims to leverage Avalia Immunotherapies' unique vaccine technology to stimulate T-cells in the liver against the malaria parasite, preventing a crucial stage of its development.

HEPATITIS B AND INFLUENZA

The same T-cell stimulating vaccine technology used in developing the malaria vaccine is also being applied to hepatitis B and influenza. Avalia Immunotherapies, who lead this immunological work, has secured significant capital to continue this programme.

Asthma & Allergy



Asthma and allergy rates are increasing globally, yet what drives these debilitating diseases remains largely a mystery.


Using state-of-the-art genetic sequencing, we are uncovering the environmental and genetic triggers that nudge the immune system towards allergic development, and investigating ways to halt or prevent this.

DENDRITIC CELLS

Dendritic cells are thought to play a key role in the development of allergies in part due to their role as 'sentinels' of the immune system. As Dendritic cells encounter antigens, they present these molecules to the rest of the immune system, shaping how the immune system responds to different substances.

International collaborations

Based at the National Institutes of Health in Bethesda, USA, Malaghan Institute International Research Fellow Dr Kerry Hilligan is working in Dr Alan Sher's laboratory as part of an international allergy research collaboration. This two-year research project is seeking to better understand how past infections or vaccinations shape and condition the immune system, especially during early development, and whether they affect the responsiveness of the immune system long-term.



Differentiating Dendritic cells

The immune cell biology team published a literature review during the March–May COVID-19 lockdown period finding that Dendritic cells in the skin act and behave in a distinctly different manner than Dendritic cells found elsewhere in the body. This may affect the way people become sensitised to allergens via the skin and is being investigated further.

Bioinformatics

A collaboration with the Weizmann Institute of Science in Israel has developed a novel method of tracking Dendritic cells in the body, using genetic sequencing techniques. This enables researchers to investigate exactly how these cells 'pick up' antigens and display them to the rest of the immune system.

GUT WORMS PROTECTING AGAINST ALLERGIC DISEASE

Providing solid evidence to a long-held theory that gut worms provide a layer of protection against allergic conditions throughout the body, the parasitology team published its latest findings in *Frontiers Immunology* showing for the first time that a gut parasite can suppress an inflammatory response in the skin.

ATOPIC DERMATITIS

The atopic dermatitis model developed at the Malaghan Institute continues to provide a solid platform for investigating allergic disease in the skin. Work being done by the translational immunology team was put on hold due to the global pandemic, including applying this model in a clinical phototherapy study.



MIDDLE IMAGE: 'Keeping an eye on you' – PhD student Jodie Chandler

An ear histological section seven days after house-dust mite immunisation. We can see swelling in the dorsal side by infiltration of helper lymphocytes (green) & myeloid macrophages (magenta) as the immune system rallies to fight the unwanted pathogen. Understanding what these immune cells are doing and how they communicate with the rest of the immune system is an important area for understanding how things like allergies are initiated.

Gut health





IMAGE: 'Gut' – Dr Johannes Mayer

Our intestine represents the largest surface area in our body and is constantly exposed to the outside world through what we eat. To protect us, the epithelial lining (blue) shields each intestinal villi (island) from microbes. Inside each of the villi immune cells (green), such as macrophages (red), are at the ready to fight infection in case something does get through.

The largest population of our immune cells reside in our gut, where our diet meets our immune system.

The gut is shaped by what we eat and the microbes that call it home, which in turn shapes how the gut interacts with the immune system. Understanding this complicated relationship has far-reaching implications for our health and wellbeing.



HOOKWORM THERAPY

The Malaghan Institute's hookworm therapy programme continues to make steady progress in unravelling how hookworms modulate and influence the human immune system, with the aim of finding better treatment options for a range of inflammatory and autoimmune diseases.

- In a first of its kind, the Institute began a clinical study of healthy volunteers – people with no pre-existing allergic or inflammatory conditions – to establish a baseline control for future trials. During the course of the infection, samples are collected from participants, tracking changes to their health and immunological profile.
- The hookworm team has also received ethical approval to begin clinical hookworm trials, in collaboration with Dr Stephen Inns from the University of Otago, Wellington and Dr Thomas Mules from the Hutt Valley District Health Board to administer worms to patients with the inflammatory bowel disease ulcerative colitis.
- Similar trials for perennial allergic rhinitis (hay fever) and eosinophilic esophagitis – a chronic, allergic inflammatory disease of the oesophagus – are in development.

METABOLIC HEALTH

To better understand how the immune system fuels itself – otherwise known as immune metabolism – the Translational Immunology team has recruited returning Kiwi scientist Dr David O'Sullivan. Dr O'Sullivan will be looking at nutritional components and bioactive compounds from different food groups to investigate how these influence immune cell metabolism and function.

IMPACT OF COVID-19 ON RESEARCH

Much of the Malaghan Institute's gut health work is translational – working alongside clinicians and patients. The COVID-19 restrictions placed an indefinite hold on much of this research, including the High Value Nutrition National Science Challenge, until social distancing and travelling restrictions are eased.

Brain health

The brain was once thought to be largely separated from cells of the immune system.

However, we now know this is not the case, and the immune system has a role to play in not only the progression of brain cancer and neurodegenerative diseases, but also in their potential treatment, repair and recovery.

NEURODEGENERATIVE DISEASE

Cancer Cell Biology Team Leader Professor Mike Berridge was awarded an HRC Explorer Grant to investigate mitochondrial dysfunction in the brain as a novel early-detection test for neurodegenerative disease. This grant builds on the existing collaboration between the Malaghan Institute and Victoria University of Wellington's Professor Bart Ellenbroek and Dr Darren Day, exploring mitochondrial involvement in brain diseases like depression, autism and neurodegeneration, including Parkinson's disease.

MULTIPLE SCLEROSIS

Multiple sclerosis research at the Malaghan Institute is focused on both the suppression of harmful inflammation in the brain as well the promotion of recovery of damaged neurons. In 2019, MS Team Leader Professor Anne La Flamme was named patron of the Wellington MS Society.

CRISP trial results


Results from the CRISP trial were published, showing unexpected results in how MS patients responded to the atypical antipsychotic drug clozapine. MS patients enrolled in the trial all displayed unexpected sensitivities to the drug, indicating further investigation was needed to understand how this drug works and why MS patients display increased sensitivity. The MS team published a manuscript detailing that in animal MS models, clozapine inhibits chemotaxis, preventing correct signalling of immune cells in and out of the brain.

Promoting recovery

A collaboration between Victoria University of Wellington's Associate Professor Bronwyn Kivell, University of Kentucky's Professor Thomas Prinszano and MS Team Leader Anne La Flamme, formed the company Rekovery to commercialise a treatment for the remyelination of neural cells.



Technology



Technology is the foundation on which advancements in medical research are made.

It is the generous support of organisations like the Hugh Green Foundation, the Lion Foundation, the Infinity Foundation and Freemasons New Zealand that position the Malaghan Institute at the forefront of cutting-edge research.

HUGH GREEN CYTOMETRY CENTRE

The Hugh Green Cytometry Centre is continuing to build momentum as New Zealand's go-to centre for cytomic and analytical excellence. The goal of the platform is to provide complete cell to organism analysis – offering scientists tools to analyse both the macro (structures and tissues) and the micro (cells and genes).

Genomic sequencing

The increasing demand for genomics – the ability to analyse the structure and expression of genes within individual cells – across the Institute's research programmes, has led to the establishment of a dedicated genomics sequencing platform. The platform will provide in-house tools and expertise, with the support of a dedicated technician, to look at what genes are doing in the context of disease.

Building a world-class cytomics platform

As technology advances towards high-dimensional data analysis, the Hugh Green Cytometry Centre has been developing its capabilities to provide high-throughput, high-dimensional technology platforms that will allow for high-speed data capture and analysis. This has included recent purchases of a confocal microscope for three-dimensional imaging, and an on-chip large-particle sorter, crucial for clinical research such as the therapeutic hookworm trial.

BIOMEDICAL RESEARCH UNIT

The COVID-19 Level 4 lockdown posed a unique challenge to our biomedical research unit staff, with the team tasked with caring for the Institute's mice. Even though this work was classified as essential, social distancing and number limits for laboratories created significant obstacles to daily operations, requiring creative solutions to ensure the same level of service and care.

The team also provided cutting-edge in vitro fertilisation techniques to enable appropriate preclinical models for testing COVID-19 vaccine candidates to be brought to New Zealand.



Principal Investigators



PROFESSOR GRAHAM LE GROS, DIRECTOR

CNZM, FRSNZ, FRCPA (HON), BSC
(MASSEY), DIP IMMUNOL (OTAGO), MPHIL
PHD (AUCKLAND)

Appointed 1994

Professor Le Gros is Research Director and leads both the asthma, allergy and parasitic disease, and hookworm clinical therapy research programmes. His research focuses on understanding how the immune system responds to allergens or parasites in the skin and lung.



PROFESSOR ANNE LA FLAMME

BS(MIT), MS, PHD (WASHINGTON)

Appointed 2008

Professor La Flamme heads the multiple sclerosis research programme. Her research focuses on discovering new treatments and therapies for MS, including ways to both prevent harmful neural inflammation and to promote recovery of neural cells for MS patients.



PROFESSOR MIKE BERRIDGE

BSC, MSC(HONS), PHD (AUCKLAND)
Appointed 1976

Professor Berridge leads the cancer cell biology research programme. His current research interests include cancer cell energy metabolism in relation to neurodegenerative disease, and mitochondrial gene transfer between cells in cancer settings.



PROFESSOR FRANCA RONCHESE

PHD (PADUA), DIP MICROBIOLOGY
Appointed 1994

Professor Ronchese leads the immune cell biology research programme. The goal of this programme is to identify the unique signals that drive the initiation of allergic immune responses with the goal of finding new opportunities to prevent the development of allergic conditions.



PROFESSOR IAN HERMANS

BSC(HONS) (OTAGO), MSC(DISTINC) (OTAGO), PHD (WELL)
Appointed 2005

Professor Hermans is the Deputy Director of Research and leads the cancer immunotherapy research programme. The main goals of his research are designing more effective vaccines and immunotherapies against cancer.



DR OLIVIER GASSER

MSC (STRASBOURG), PHD (BASEL)
Appointed 2017

Dr Gasser leads the translational immunology programme. His research investigates ways to leverage communication between the immune system and metabolism, with an emphasis on nutrition and gut resident microbes, to design new therapies to improve human health.



DR ROBERT WEINKOVE

MA (CANTAB), MBBS (HONS), PHD, FRACP, FRCP
Appointed 2018

Dr Weinkove is Clinical Director and leads the Freemasons CAR T-cell Research Programme as well as the ENABLE clinical trial. He is also in clinical practice as a consultant haematologist at the Wellington Blood & Cancer Centre, Capital and Coast District Health Board.



DR LISA CONNOR

PHD (OTAGO), BMEDSC(HONS) (WELL)
Appointed 2018

Dr Connor leads the Vaccine Alliance Aotearoa New Zealand – Ohu Kaupare Huaketo vaccine evaluation team, tasked with assessing potential vaccine candidates for the ability to stimulate appropriate immune responses against the COVID-19 virus.

Publications

Boykin LM, Sseruwagi P, Alicai T, Ateka E, Mohammed IU, Stanton JL, Kayuki C, Mark D, Fute T, Erasto J, Bachwenkizi H, Muga B, Mumo N, Mwangi J, Abidrabo P, Okao-Okuja G, Omuut G, Akol J, Apio HB, Osingada F, Kehoe MA, Eccles D, Savill A, Lamb S, Kinene T, Rawle CB, Muralidhar A, Mayall K, Tairo F, Ndunguru J (2019). Tree Lab: Portable genomics for Early Detection of Plant Viruses and Pests in Sub-Saharan Africa. **Genes (Basel)**. 10(9):632

Pellefigues C, Mehta P, Prout MS, Naidoo K, Yumnam B, Chandler J, Chappell S, Filbey K, Camberis M, Le Gros G (2019). The Basoph8 Mice Enable an Unbiased Detection and a Conditional Depletion of Basophils. **Front Immunol**. 10:2143

Dickinson M, Weinkove R (2019). Maintaining a fit T-cell compartment: lymphoma treatment sequencing in the era of chimeric antigen receptor T-cell therapies. **Intern Med J**. 49(10):1338

La Flamme AC (2019). Immunology & Cell Biology Publication of the Year Awards 2018. **Immunol Cell Biol**. 97(10):857-858

Clark DW, Eccles D, et al (2019). Associations of autozygosity with a broad range of human phenotypes. **Nat Commun**. 10(1):4957

Mayer JU (2019). Commentary: Spatiotemporal Modeling of the Key Migratory Events During the Initiation of Adaptive Immunity. **Front Immunol**. 10:2311

Schmidt AJ, Mayer JU, Wallace PK, Ronchese F, Price KM (2019). Simultaneous Polychromatic Immunofluorescent Staining of Tissue Sections and Consecutive Imaging of up to Seven Parameters by Standard Confocal Microscopy. **Curr Protoc Cytom**. 91(1):e64

Czechowska K, Lannigan J, Aghaepour N, Back JB, Begum J, Behbehani G, Bispo C, Bitoun D, Fernández AB, Boova ST, Brinkman RR, Ciccolella CO, Cottle B, Davies D, Dela Cruz GV, Del Rio-Guerra R, Des Lauriers-Cox AM, Douagi I, Dumrese C, Bonilla Escobar DL, Estevam J, Ewald C, Fossum A, Gaudillière B, Green C, Groves C, Hall C, Haque Y, Hedrick MN, Hogg K, Hsieh EWY, Irish J, Lederer J, Leipold M, Lewis-Tuffin LJ, Litwin V, Lopez P, Nasdala I, Nedbal J, Ohlsson-Wilhelm BM, Price KM, Rahman AH, Rayanki R, Rieger AM, Robinson JP, Shapiro H, Sun YS, Tang VA, Tesfa L, Telford WG, Walker R, Welsh JA, Wheeler P, Tárnok A (2019). Cyt-Geist: Current and Future Challenges in Cytometry: Reports of the CYTO 2019 Conference Workshops. **Cytometry A**. 95(12):1236-1274

Lange J, Anderson RJ, Marshall AJ, Chan STS, Bilbrough TS, Gasser O, Gonzalez-Lopez C, Salio M, Cerundolo V, Hermans IF, Painter GF (2020). The Chemical Synthesis, Stability, and Activity of MAIT Cell Prodrug Agonists That Access MR1 in Recycling Endosomes. **ACS Chem Biol**. 15(2):437-445

La Flamme AC (2020). Immunology & Cell Biology's Top 10 original research articles 2018–2019. **Immunol Cell Biol**. 98(1):6–8

Stanworth SJ, Killick S, McQuilten ZK, Karakantza M, Weinkove R, Smethurst H, Pankhurst LA, Hodge RL, Hopkins V, Thomas HL, Deary AJ, Callum J, Lin Y, Wood EM, Buckstein R, Bowen D; REDDS Investigators (2020). Red cell transfusion in outpatients with myelodysplastic syndromes: a feasibility and exploratory randomised trial. **Br J Haematol**. 189(2):279-290

Mehta S, McKinney C, Algie M, Verma CS, Kannan S, Harfoot R, Bartolec TK, Bhatia P, Fisher AJ, Gould ML, Parker K, Cesare AJ, Cunliffe HE, Cohen SB, Kleffmann T, Braithwaite AW, Woolley AG (2020). Dephosphorylation of YB-1 is Required for Nuclear Localisation During G2 Phase of the Cell Cycle. **Cancers (Basel)**. 12(2):315

Ferrer-Font L, Mehta P, Harnos P, Schmidt AJ, Chappell S, Price KM, Hermans IF, Ronchese F, Le Gros G, Mayer JU (2020). High-dimensional analysis of intestinal immune cells during helminth infection. **Elife**. 9:e51678

George P, Dasyam N, Giunti G, Mester B, Bauer E, Andrews B, Perera T, Ostapowicz T, Frampton C, Li P, Ritchie D, Bollard CM, Hermans IF, Weinkove R (2020). Third-generation anti-CD19 chimeric antigen receptor T-cells incorporating a TLR2 domain for relapsed or refractory B-cell lymphoma: a phase I clinical trial protocol (ENABLE). **BMJ Open**. 10(2):e034629

Robichon K, Patel V, Connor B, La Flamme AC (2020). Clozapine reduces infiltration into the CNS by targeting migration in experimental autoimmune encephalomyelitis. **J Neuroinflammation**. 17(1):53

Bouchery T, Moyat M, Sotillo J, Silverstein S, Volpe B, Coakley G, Tsourouktoglou TD, Becker L, Shah K, Kulagin M, Guet R, Camberis M, Schmidt A, Seitz A, Giacomini P, Le Gros G, Papayannopoulos V, Loukas A, Harris NL (2020). Hookworms Evade Host Immunity by Secreting a Deoxyribonuclease to Degrade Neutrophil Extracellular Traps. **Cell Host Microbe**. 27(2):277-289.e6

Shepherd AL, Smith AAT, Wakelin KA, Kuhn S, Yang J, Eccles DA, Ronchese F (2020). A semi-automated technique for adenoma quantification in the ApcMin mouse using FeatureCounter. **Sci Rep**. 10(1):3064

Ferrer-Font L, Pellefigues C, Mayer JU, Small SJ, Jaimes MC, Price KM (2020). Panel Design and Optimization for High-Dimensional Immunophenotyping Assays Using Spectral Flow Cytometry. **Curr Protoc Cytom**. 92(1):e70

Giladi A, Cohen M, Medaglia C, Baran Y, Li B, Zada M, Bost P, Blecher-Gonen R, Salame TM, Mayer JU, David E, Ronchese F, Tanay A, Amit I (2020). Dissecting cellular crosstalk by sequencing physically interacting cells. **Nat Biotechnol**. 38(5):629-637

Dasyam N, George P, Weinkove R (2020). Chimeric antigen receptor T-cell therapies: Optimising the dose. **Br J Clin Pharmacol**. 86(9):1678-1689

Lasham A, Tsai P, Fitzgerald SJ, Mehta SY, Knowlton NS, Braithwaite AW, Print CG (2020). Accessing a New Dimension in TP53 Biology: Multiplex Long Amplicon Digital PCR to Specifically Detect and Quantitate Individual TP53 Transcripts. **Cancers (Basel)**. 12(3):769

Li Y, Woods K, Parry-Strong A, Anderson RJ, Capistrano C, Gestin A, Painter GF, Hermans IF, Krebs J, Gasser O (2020). Distinct Dysfunctional States of Circulating Innate-Like T Cells in Metabolic Disease. **Front Immunol**. 11:448

Woodhead JST, D'Souza RF, Hedges CP, Wan J, Berridge MV, Cameron-Smith D, Cohen P, Hickey AJR, Mitchell CJ, Merry TL (2020). High-intensity interval exercise increases humanin, a mitochondrial encoded peptide, in the plasma and muscle of men. **J Appl Physiol (1985)**. 128(5):1346-1354

Ferrer-Font L, Mayer JU, Old S, Hermans IF, Irish J, Price KM (2020). High-Dimensional Data Analysis Algorithms Yield Comparable Results for Mass Cytometry and Spectral Flow Cytometry Data. **Cytometry A**. 97(8):824–831

Grasso C, Field CS, Tang CW, Ferguson PM, J Compton B, Anderson RJ, Painter GF, Weinkove R, F Hermans I, Berridge MV (2020). Vaccines adjuvanted with an NKT cell agonist induce effective T-cell responses in models of CNS lymphoma. **Immunotherapy**. 12(6):395-406

Fabre MS, Stanton NM, Slatter TL, Lee S, Senanayake D, Gordon RMA, Castro ML, Rowe MR, Taha A, Royds JA, Hung N, Melnick AM, McConnell MJ (2020). The oncogene BCL6 is up-regulated in glioblastoma in response to DNA damage, and drives survival after therapy. **PLoS One**. 15(4):e0231470

Ussher JE, Le Gros G, Quiñones-Mateu ME, Gulab SA, Yiannoutsos M (2020). The case for New Zealand to have its own COVID-19 vaccine programme. **NZ Med J**. 133(1513):112-115

George P, Brown A, Weinkove R (2020). B-cell Prolymphocytic Leukaemia With a t(4;14) FGFR3/IGH Translocation: Response to Ibrutinib. **Pathology**. 52(4):491-492

Ronchese F, Hilligan KL, Mayer JU (2020). Dendritic Cells and the Skin Environment. **Curr Opin Immunol**. 64:56-62

Bosteels C, Neyt K, Vanheerswynghe M, van Helden MJ, Sichien D, Debeuf N, De Prijck S, Bosteels V, Vandamme N, Martens L, Saeys Y, Louagie E, Lesage M, Williams DL, Tang SC, Mayer JU, Ronchese F, Scott CL, Hammad H, Guilliams M, Lambrecht BN (2020). Inflammatory Type 2 cDCs Acquire Features of cDC1s and Macrophages to Orchestrate Immunity to Respiratory Virus Infection. **Immunity**. 52(6):1039-1056.e9

Shrestha R, Petley EV, Farrand KJ, Jamieson SA, Jiao W, Teesdale-Spittle PH, Hermans IF, Mace PD, Rendle PM (2020). The Synthesis and Anti-tumour Properties of Poly Ethoxy Ethyl Glycinamide (PEE-G) Scaffolds with Multiple PD-1 Peptides Attached. **ChemMedChem**. 15(13):1128-1138

Weinkove R, McQuilten ZK, Adler J, Agar MR, Blyth E, Cheng AC, Conyers R, Haeusler GM, Hardie C, Jackson C, Lane SW, Middlemiss T, Mollee P, Mulligan SP, Ritchie D, Ruka M, Solomon B, Szer J, Thursky KA, Wood EM, Worth LJ, Yong MK, Slavin MA, Teh BW (2020). Managing haematology and oncology patients during the COVID-19 pandemic: interim consensus guidance. **Med J Aust**. 212(10):481-489

Di Ciaccio P, McCaughan G, Trotman J, Ho PJ, Cheah CY, Gangatharan S, Wight J, Ku M, Quach H, Gasiorowski R, Polizzotto MN, Prince HM, Mulligan S, Tam CS, Gregory G, Hapgood G, Spencer A, Dickinson M, Latimer M, Johnston A, Armytage T, Lee C, Cochrane T, Berkahn L, Weinkove R, Doocey R, Harrison SJ, Webber N, Lee HP, Chapman S, Campbell BA, Gibbs SDJ, Hamad N (2020). Australian and New Zealand consensus statement on the management of lymphoma, chronic lymphocytic leukaemia and myeloma during the COVID-19 pandemic. **Intern Med J**. 50(6):667-679

Hilligan KL, Ronchese F (2020). Antigen presentation by dendritic cells and their instruction of CD4+ T helper cell responses. **Cell Mol Immunol**. 17(6):587-599

Filbey KJ, Mehta PH, Meijlink KJ, Pellefigues C, Schmidt AJ, Le Gros G (2020). The Gastrointestinal Helminth Heligmosomoides bakeri Suppresses Inflammation in a Model of Contact Hypersensitivity. **Front Immunol**. 11:950

Reddington K, Eccles D, O'Grady J, Drown DM, Hansen LH, Nielsen TK, Ducluzeau AL, Leggett RM, Heavens D, Peel N, Snutch TP, Bayega A, Oikonomopoulos S, Ragoussis I, Barry T, van der Helm E, Jolic D, Richardson H, Jansen H, Tyson JR, Jain M, Brown BL (2020). Metagenomic analysis of planktonic riverine microbial consortia using nanopore sequencing reveals insight into river microbe taxonomy and function. **Gigascience**. 9(6):giaa053

Holz LE, Chua YC, de Menezes MN, Anderson RJ, Draper SL, Compton BJ, Chan STS, Mathew J, Li J, Kedzierski L, Wang Z, Beattie L, Enders MH, Ghilas S, May R, Steiner TM, Lange J, Fernandez-Ruiz D, Valencia-Hernandez AM, Osmond TL, Farrand KJ, Seneviratna R, Almeida CF, Tullett KM, Bertolino P, Bowen DG, Cozijnsen A, Mollard V, McFadden GI, Caminschi I, Lahoud MH, Kedzierska K, Turner SJ, Godfrey DI, Hermans IF, Painter GF, Heath WR (2020). Glycolipid-peptide vaccination induces liver-resident memory CD8+ T cells that protect against rodent malaria. **Sci Immunol**. 5(48):eaaz8035

Jayasinghe TN, Vatanen T, Chiavaroli V, Jayan S, McKenzie EJ, Adriaenssens E, Derraik JGB, Ekblad C, Schierding W, Battin MR, Thorstensen EB, Cameron-Smith D, Forbes-Blom E, Hofman PL, Roy NC, Tannock GW, Vickers MH, Cutfield WS, O'Sullivan JM (2020). Differences in Compositions of Gut Bacterial Populations and Bacteriophages in 5-11 Year-Olds Born Preterm Compared to Full Term. **Front Cell Infect Microbiol**. 10:276

Tang JS, Compton BJ, Marshall A, Anderson R, Li Y, van der Woude H, Hermans IF, Painter GF, Gasser O (2020). Mānuka honey-derived methylglyoxal enhances microbial sensing by mucosal-associated invariant T cells. **Food Funct**. 11(7):5782-5787

Borger JG, Le Gros G, Kirman JR (2020). Editorial: The Role of Innate Lymphoid Cells in Mucosal Immunity. **Front Immunol**. 11:1233

Chauché C, Vacca F, Chia SL, Richards J, Gregory WF, Ogunkanbi A, Wear M, McSorley HJ (2020). A Truncated Form of HpARI Stabilizes IL-33, Amplifying Responses to the Cytokine. **Front Immunol**. 11:1363



Lamielle O, Mayer JU, Munoz-Erazo L, Ronchese F (2020). Dendritic cells in Th2 immune responses and allergic sensitisation. **Immunol Cell Biol**. 10.1111/imcb.12387

Paton KF, Biggerstaff A, Kaska S, Crowley RS, La Flamme AC, Prinszano TE, Kivell BM (2020). Evaluation of Biased and Balanced Salvinorin A Analogs in Preclinical Models of Pain. **Front Neurosci**. 14:765

Kawabe T, Yi J, Kawajiri A, Hilligan K, Fang D, Ishii N, Yamane H, Zhu J, Jankovic D, Kim KS, Trinchieri G, Sher A (2020). Author Correction: Requirements for the differentiation of innate T-bethigh memory-phenotype CD4+ T lymphocytes under steady state. **Nat Commun**. 11(1):3366

Berridge MV, Herst PM, Grasso C (2020). Mitochondrial movement between mammalian cells: an emerging physiological phenomenon. **ScienceDirect**. 20:515-546

Financial overview



FINANCIAL PERFORMANCE

For the year ended 31 July 2020

	2020	2019
REVENUE		
Grants revenue	8,919,112	7,366,157
Philanthropic revenue	6,257,478	5,912,129
Investment revenue	633,159	1,298,344
Other revenue	79,816	141,716
	15,889,564	14,718,346
EXPENSES		
Depreciation	873,721	809,621
Facilities costs	1,236,003	1,267,480
Lab costs	2,459,190	2,598,875
Other costs	1,630,225	1,514,547
People costs	7,044,490	6,204,222
	13,243,629	12,394,746
SURPLUS/(DEFICIT)	2,645,935	2,323,600
Share of surplus/(deficit) of associate	(58,146)	(122,680)
Impairment of investment in associate	(471,873)	-
Total Comprehensive Revenue and Expense	2,115,916	2,200,920

FINANCIAL POSITION

As at 31 July 2020

	2020	2019
	Consolidated	Consolidated
ASSETS		
Current Assets	19,015,280	14,906,181
Non-Current Assets	7,686,395	8,301,909
	26,701,675	23,208,090
LIABILITIES		
Current Liabilities	3,388,493	2,010,825
	3,388,493	2,010,825
NET ASSETS	23,313,181	21,197,265

Philanthropic highlights



All support positively shapes the Malaghan Institute. Not matter what form, whether it be financial, advocacy or in kind, it is incredibly valued by all our staff.

I would direct all who are reading this to turn to the funding page. The many names and organisations listed paints a clear picture that support for independent biomedical research in New Zealand is valued by people from all walks of life.

In my time at the Malaghan Institute, I have really enjoyed seeing the next generation of families and supporters getting in behind the Institute. What started off as mum and dad supporters continues as we build on long-lasting relationships. The Dr Marjorie Barclay Trust along with the Hugh Green and Thompson Foundations are good examples of this. It is also a testament to the hard work Graham and Franca put in the early years of the Institute, and we're seeing these early efforts paying off in the community.

The Malaghan Friends are also a big part of this. As our advocates in the community, they are second to none and I have had the immense enjoyment and privilege of working side by side with them.

From the moment Prime Minister Ardern announced New Zealand would be going into Alert Level 4 lockdown, we were inundated by phone calls and messages from our supporters, wanting to know what we needed, and what they could do to help us. It was extremely uplifting to know that our supporters wanted to make sure that we were OK during these uncertain times, and that their hard-earned support didn't lose momentum or flounder while New Zealand came to grips with the 'new normal.'

I am continually impressed by the engagement and care our supporters show in our research and the direction we're heading.

Philanthropic giving enables us to use technology and equipment at the cutting-edge. Even though we're on the other side of the world from the big labs, we stand shoulder to shoulder in terms of capability and output. The Institute is often used as a location to trial new advanced pieces of technology, a position that benefits us by way of accelerating the overall pace of our research. Our independent status as a charity allows us the freedom and flexibility to seize on such opportunities.

The investment in young scientists is the other essential area for philanthropic support. Whether it be through tuition, professional development or international travel opportunities, the willingness to back future leading scientists is something the New Zealand community is deeply committed to.

As I step down from my role as Head of Development, I wish to express just how eternally grateful I am across the board, and how lucky we are at the Malaghan Institute to have such a wonderful support base who really care about the Institute and its activities, and are totally engaged with what we're doing.

Thank you,

Jenny Sim | HEAD OF DEVELOPMENT



Funding

We are honoured to receive support from many individuals, organisations, businesses and trusts. Although we can only name a few here, your support is invaluable and ensures our research can continue to improve human health.

Thank you. We also thank those supporters who wish to remain anonymous.

TRUSTS AND FOUNDATIONS

Andrew Smith Family Trust
 BEA Trust
 Black and White Golfers Trust
 Brown Chapman Family Trust
 Cancer Society of New Zealand
 Cancer Society of New Zealand Wellington Division
 Carol Tse (No 2) Family Trust
 Clegg Family Charitable Trust
 Colin Williamson Charitable Trust
 Dairy Goat Co-Operative (NZ) Ltd
 David Levene Foundation
 Dr Marjorie Barclay Charitable Trust
 Edith Rose Isaacs Estate
 Florence Petersen Leukaemia Trust
 Freemasons New Zealand
 Frimley Foundation
 Glenpark Foundation
 Grady Grant
 Health Research Council of New Zealand
 Helen Graham Charitable Trust
 Hugh Green Foundation
 Infinity Foundation Limited (Grassroots Trust Central Limited from August 2020)
 James Russell Lewis Trust
 Jennifer Smith Family Trust
 John and Margaret Hunn Education Trust
 John Holt Memorial Trust
 Keith Seagar Research Fund
 KIA Taylor Charitable Trust
 Kiwi Innovation Network
 Leukaemia & Blood Cancer New Zealand
 Lois McFarlane Charitable Trust
 Loyal Orange Lodge No 20
 Lundquist-Galvin Family Trust
 Marsden Fund (Royal Society Te Aparangi)
 Maurice and Phyllis Paykel Trust
 Maurice Capstick Medical Trust
 Maurice Wilkins Centre
 McDonald Family Trust
 Merrilees Family Charitable Trust
 Michael Jull Trust
 Ministry of Business, Innovation & Employment
 Nikau Foundation
 Pelorus Trust
 Pinel Family Trust
 Prostate Cancer Foundation of New Zealand
 Research for Life
 Rex & Betty Coker Foundation
 SJ Shayle-George Charitable Trust
 SE Leuchars Family Trust
 Society for Mucosal Immunology
 The Estates of Ellen, Sinclair, Barbara and Alison Wallace
 The Great New Zealand Trek Charitable Trust Inc
 The Herbert Teagle Masonic Perpetual Trust
 The Lawrence and Stephanie Russell Charitable Trust
 The Lion Foundation
 The Margaret Ann Tibbles Charitable Trust
 The Margaret Neave Charitable Foundation
 The Miriam Stephen Charitable Trust
 The Nick Lingard Foundation
 The Paddy Brow Charitable Trust
 The Sydney and Angela Cumming Charitable Trust
 The Thompson Family Foundation Inc
 The Wayfarers Lodge No. 389
 Tonks Family Foundation Limited
 University of Otago
 Victoria University of Wellington
 Walter and Rana Norwood Charitable Trust

RESEARCH PARTNERS

Acurity Health Group Limited
Bolton Hotel
Kinetics Group Ltd
Mediray New Zealand
Succession First NZ
Thermo Fisher Scientific
Trade Balers
Walker & Hall Fine Gifts Ltd
Zephyr Consulting Limited

STRATEGIC PARTNERS

Freemasons New Zealand
Hugh Green Foundation
International Waste Limited (Interwaste)
Jarden
Just Paterson Real Estate
Lexus New Zealand
Lexus of Auckland City
Lexus of Christchurch
Lexus of Hamilton
Lexus of Hawke's Bay
Lexus of North Shore
Lexus of Queenstown
Lexus of Wellington
SenateSHJ
Spy Valley Wines
System Consultancy Services Sdn Bhd

CHARITY OF CHOICE PARTNERS

Combined Lions Club of Kāpiti
Crombie Lockwood Wellington
Down with Cancer – David Downs
GBL Personnel
Just Paterson Real Estate Ltd
Microsoft NZ
The Rotary Club of Port Nicholson
Waikanae Lions Club

IN CELEBRATION

Brian Bennett
David Bichan
John Bongiovanni
Dorothy Brady
Stephanie Briggs
George Bright
Robert Burton
Wayne Chapman
Glenn Duncan
Betty Empson
Patricia Englert
Lina Ferguson
Ross Gasson
Marion Gilmour
William Hallett
Sally Ann Hansen
Jill Kinloch
Velna McConchie
Michael Morris
Mike Morris
Ian Paterson
Sally Rose Paterson
Vivienne Paterson
Gary Roselli
Donald Scott
Mark and Juliet Tinkle
Tim Wild

BEQUESTS

Barbara Elisabeth Anderson
Raymond Stanley Boyce
Florence Quentin Davies
Alys Shirley Margaret Furkert
Dorothy May Hardie
Keitha Jennifer Mary Holyoake
Jill Kinloch
Edward Malcolm Morgan
Yvonne Morgans
Corinne Shirley Opie
Joan Robertson
Gwenda Tasker
Dorothy Marjorie Vandenberg
Phillis Jane Williams

COMMUNITY SUPPORTERS

We would like to acknowledge and thank the many Friends of the Malaghan Institute including Chairs Linda Robert (Auckland), Kimberley and Peter Mitchell (Tauranga), Rick Hart (Taupō), Denise Bull (Hawke's Bay), Kelly Sutton (Wellington), as well as all our event supporters and community groups. We gratefully appreciate their generosity with their time and fundraising efforts.

Trust board



GRAHAM MALAGHAN

ONZM, FCILT, HON DCS (WELL) (CHAIRMAN)

Graham was appointed Chairman of the Trust Board in 1990. He was first employed at General Foods Corp in 1967, and was appointed General Manager of Refrigerated Freight Lines in 1970, acquiring the company in 1987. Graham was founding Chairman of Tasman Express Line and a member of the Land Transport Safety Authority for six years. In 2009 he was awarded an Honorary Doctorate of Science from Victoria University of Wellington for his key role in rebuilding the Malaghan Institute into the largest independent medical research organisation in New Zealand. Recipient of the Sir Bob Owens award in 2010 for contributions to the transport, logistics industries and the community, Graham was made an Officer of the Order of Merit for his services to medical research and philanthropy in 2012. His current directorships include several private companies.



PROF GRAHAM LE GROS

CNZM, FRSNZ, FRCPA (HON), BSC (MASSEY), DIP IMMUNOL (OTAGO), MPHIL PHD (AUCKLAND) (DIRECTOR)

Graham was appointed to the Trust Board in 1995. Awarded a Fogarty Fellowship at the National Institutes of Health, Washington DC from 1987-1989, Graham then took a scientist position with Ciba-Geigy in Basel Switzerland for five years before returning to New Zealand to take up the position of Research Director of the Malaghan Institute in 1994. Graham is a Professor of the School of Biological Sciences, Victoria University of Wellington. A Fellow of the Royal Society of New Zealand, in 2014 he was made a Companion of the New Zealand Order of Merit for his services to medical research.



JOHN BEATTIE

LLB (WELL), MAICD

John was appointed to the Trust Board in 1991 and is a director of Malcorp Biodiscoveries Limited, a subsidiary of the Malaghan Institute, and a director of Wellington Zhaotai Therapies Ltd. After obtaining a law degree from Victoria University of Wellington in 1975, John was a Fulbright Scholar to Cornell University in 1979. He is a governor of the NZ Sports Hall of Fame and a trustee of the NZ Diabetes Foundation. John has been a partner in national law firm Kensington Swan, a General Manager of Brierley Investments Limited and was the co-founder of Genesis Research and Development Corporation Limited with the late Professor Jim Watson, a former trustee of the Malaghan Institute.



TIM BENNETT

BCOM, MBA

Tim was appointed to the Trust Board in 2019. Tim is an experienced senior executive and strategic advisor with extensive experience in the capital, commodity and financial markets in New Zealand, the United States, Australia and Asia. His executive roles have included Chief Executive Officer of NZX from 2012–2017, and a Partner of Oliver Wyman and the Boston Consulting Group. He is a director of Partners Life, AIX and Avalia Immunotherapies.



ASSOC PROF JOHN CARTER

MNZM, BBIOMEDSCI, MBCHB, FRACO, FRACP(RET)

John was appointed to the Trust Board in 2003. He is an Associate Professor of the University of Otago and clinically practises as a haematologist with a focus on stem cell transplantation. John undertook postgraduate work at the Fred Hutchinson Cancer Research Center and the University of Washington. He is the past Chair of both the New Zealand Blood Service and Scots College, and has recently retired as Medical Leader of the Wellington Blood and Cancer Centre.



SIR PAUL COLLINS

KNZM, BCA, ACA

Sir Paul was appointed to the Trust Board in 2019. He also currently chairs the Wairarapa District Health Board and Active Equity Holdings Limited, and is a director of the Hurricanes Limited, Shott Beverages Limited, NZ Health Partnerships Ltd, and Central Region's Technical Advisory Services Ltd. The former Chief Executive of Brierley Investments has served on the board of more than 50 listed companies globally and extensively in sports governance, including as Chairman of Sport New Zealand and High Performance Sport New Zealand Limited. He is an Associate Chartered Accountant and holds a bachelor's degree in Commerce and Administration from Victoria University of Wellington. In 2015, he was made a Knight Companion of the New Zealand Order of Merit for services to sports governance.



PROF PARRY GUILFORD

MSC (OTAGO), PHD (CU), FRSNZ

Parry was appointed to the Trust Board in 2019. Parry is Director of the Cancer Genetics Laboratory and the Centre for Translational Cancer Research (Te Aho Matatū) at the University of Otago. He is a co-founder of the publicly listed biotechnology company Pacific Edge Ltd, and a Deputy Director of the Healthier Lives National Science Challenge. His current research interests include the genetics of inherited and sporadic cancers, in particular stomach cancer. Other active research areas are the development of genomic-based diagnostic tools for early cancer detection and personalised medicine.



PROF DAVE HARPER

BA (HONS) (OTAGO), MA PHD (CANT)

Dave was appointed to the Trust Board in 2019. He was appointed Dean of Science in November 2014. Dave came to Te Herenga Waka – Victoria University of Wellington in 1994 as a lecturer in Psychology and was promoted to professor in 2013. He was head of the School of Psychology between 2006 and 2010, Deputy Dean of the Faculty of Science between 2012 and 2014, and Acting Pro-Vice Chancellor of the Faculties of Science, Engineering, Architecture & Design Innovation in 2019. Dave's research interests include the comparison of learning processes across animal species, laboratory analogues to study attention and decision making, the impact of drugs of abuse on cognition, and the comparative roles played by the brain's neurochemical systems, serotonin, and dopamine in memory function.



BRYAN JOHNSON

ONZM, BCA (WELL)

Bryan was appointed to the Trust Board in 1998. Graduating with a commerce degree from Victoria University of Wellington in 1963, he was a senior partner in the stockbroking company Jarden & Co for 25 years, becoming Chairman after the sale of the business to Credit Suisse First Boston in 1991. Bryan retired from Credit Suisse First Boston in 2000 to further develop his Marlborough winery and vineyard, Spy Valley. He has been a director of various corporations, including Brierley Investments and Royal Sun Alliance and was Chairman of the Duke of Edinburgh's Award and a trustee of the Wellington Stadium Trust. Bryan is also the Founder President of Jarden. In 2015 he was made Officer of the New Zealand Order of Merit for his services to business and philanthropy.



DR DIANNE MCCARTHY

CNZM, CRSNZ, BA MSC (HONS) PHD (AUCKLAND)

Dianne was appointed to the Trust Board in 2015. Dianne was Chief Executive of the Royal Society of New Zealand from 2007–2014, and has more than 25 years' experience in various senior management and governance roles in the tertiary education, science and health sectors. She is Deputy Chair of the Board of the New Zealand Institute of Economic Research, a director of the Bragato Research Institute, and a member of the governance groups of the Dodd-Walls Centre for Photonic and Quantum Technologies, and two National Science Challenges – Ageing Well and Healthier Lives. She is on the Victoria University of Wellington Council and a trustee of the Hearing Research Foundation (NZ). Dianne was made an Officer of the New Zealand Order of Merit for services to education in 2008, a Companion of the Royal Society of New Zealand for services to science in 2015, and a Companion of the New Zealand Order of Merit for services to science, business and women in 2016.



DAVID MOSSMAN

QSM, BVSC (UQ), MRCVS, MNZIF

David was appointed to the Trust Board in 2005. He attended Lincoln College before graduating from the University of Queensland in 1965 with a veterinary degree. David was awarded the Australian College of Veterinary Scientists college prize in 1978 and in 1984 the Coopers' NZ Farm Management Award for significant innovative farm management in New Zealand. He was keynote speaker at the World Angus and Hereford Conferences. A member of the Lindsfarne College Board from 1981-1985, David is managing director of private farming, forestry, finance and property companies. He is President of the Hawke's Bay Friends of the Malaghan Institute and retired in 2001 as a rural veterinarian. In 2012 David was awarded the Queen's Service Medal for services to veterinary science.



TONY MOSSMAN

BBS, DIP BUS STUD, CA, CMINSTD

Tony was appointed to the Trust Board in December 2019. He has been a Chartered Accountant in public practice in the Hawke's Bay region for more than 20 years after spending time in banking in both London and Wellington. Tony was Deputy Chair of Lotto NZ, and has been a trustee of the Hawke's Bay Helicopter Rescue Trust and Iona College Board of Proprietors. He holds a Business Studies degree and Diploma from Massey University and is a Chartered Accountant and Chartered Member of the New Zealand Institute of Directors. He also continues to be involved with family interests in agriculture and forestry.



NICOLA SLADDEN

LLB (WELL), MPH (BU)

Nicola was appointed to the Trust Board in July 2014. In 2015, Nicola was appointed Banking Ombudsman after four and a half years as Deputy Banking Ombudsman. She is a consultant for the World Bank, and has more than 20 years' experience in dispute resolution, a law degree from Victoria University of Wellington and a Master of Public Health from Boston University. Nicola was previously the Chief Legal Advisor at the Office of the Health and Disability Commissioner and has worked in private practice. She has published and presented on dispute resolution in New Zealand and abroad.



DAN WILLIAMS

CA

Dan was appointed to the Trust Board in 2005. He joined an antecedent firm of Deloitte in 1958 and after four years with the firm in London, was admitted as a partner in 1972. He was initially the partner responsible for establishing the tax division, then became a Business Advisory Partner. Retiring in 2001, Dan is now a consultant to Deloitte. He has a number of private company directorships with emphasis on financial management.

Te Urungi Māori

Te Urungi: the steering paddle of the waka which supports the work of the kaihoe by guiding the course.

As part of our commitment to improving health outcomes for Māori and engaging with the articles of Te Tiriti o Waitangi and the Government's Vision Mātauranga framework, the Institute established an advisory group, Te Urungi, in 2019. Te Urungi is an integral yet independent group within the Institute, providing advice to the leadership team, with an overall view being equitable health outcomes for Māori as a result of Malaghan Institute activities. The advisory group also provides guidance on engagement with and implementation of the articles of Te Tiriti o Waitangi and Vision Mātauranga.



DR CLIVE ASPIN

PHD (OTAGO), MA (WELL), BA, DIPELT, DIP TCHG
Ngāti Maru, Ngāti Whanaunga, Ngāti Tamaterā

Clive is a Senior Lecturer in Health and Postgraduate Studies Director at Te Herenga Waka – Victoria University of Wellington. He was born in Waiuku and grew up on his ancestral land of Hauraki. Clive is a Māori public health researcher whose work focuses on Māori and Indigenous health, HIV, sexuality, and chronic conditions. He was the Executive Research Officer at Ngā Pae o te Maramatanga, New Zealand's centre of Māori research excellence. He served as a ministerial appointment to the Board of the Health Research Council and as Chair of the Māori Research Committee and is a founding member of the International Indigenous Working Group on HIV and AIDS.



DR AMOHIA BOULTON

PHD (MASSEY), MA (APPLIED), BA (HONS), BA
Ngāti Ranginui, Ngai te Rangī, Ngāti Pukenga, Ngāti Mutunga, Te Ati Awa ki te Waka a Maui

Amohia is the Director of Whakauae Research Services, a tribally-owned, Indigenous health research centre in Whanganui. She also holds adjunct positions at the Health Services Research Centre, Victoria University of Wellington and in the Faculty of Health and Environmental Sciences at Auckland University of Technology. Amohia is a member of the Healthier Lives, He Oranga Hauora National Science Challenge, Governance Group Kahui Māori, a Board member of Te Kotahi Research Centre, University of Waikato, and a Technical Advisor to the National iwi Chairs' Forum.



DR MAIA BREWERTON

MBCHB, FRACP, FRCPA
Ngāti Porou, Ngāti Kahungunu

Maia is a clinical immunologist, allergist and immunopathologist. She works as a medical specialist at Auckland Hospital and heads the immunology laboratory at North Shore Hospital. She is also a Research Consultant at the Malaghan Institute. She has sat on the Māori Health Committee of the Royal Australasian College of Physicians (RACP) as well as the RACP Adult Medicine Division Committee. She is the chair of the New Zealand Clinical Immunology and Allergy Group. In partnership with Australian Clinical Immunology & Allergy Society and Allergy New Zealand, Maia has set her sights on developing a National Allergy Strategy for Aotearoa with a strong equity lens in 2021.



DR LIS ELLISON

PHD (MASSEY)
Te Ātiawa, Ngāi Tahu, Ngāti Toa Rangatira, Ngāti Raukawa

Lis is an epidemiologist with expertise in the areas of health inequities, access to care, chronic disease – specifically cancer and respiratory conditions – and health system performance. She also has a wider focus on Māori and Pasifika research/health development particularly in relation to primary health care given the significant contribution that Māori and Pasifika provider organisations make to population health and health service provision in Aotearoa New Zealand.



DR RUAKERE HOND

PHD (MASSEY), MMS (AWANUIARANGI)
Taranaki, Ngāti Ruanui, Whānua ā-Apanui

Ruakere is prominent in reo revitalisation initiatives with a particular focus on projects in Taranaki. After completing a Bachelor of Science at Waikato University, he shifted to teaching and has spent the last 30 years in Māori language acquisition through immersion with an emphasis on community learning and using Te Ataarangi – The Silent Way approach. His doctoral research explored Māori language revitalisation as a key element of Māori health promotion. Ruakere is a current Waitangi Tribunal member and has held governance roles in Te Taura Whiri i te Reo Māori – the Māori Language Commission and Te Mātāwai, the national community Māori language board.



DR WILLY-JOHN MARTIN

PHD (WELL), MSC, BSC
Ngāti Wai, Ngāti Whātua, Ngāti Tamaterā, Ngāti Porou

Willy-John is the Manager Vision Mātauranga and Capacity Development for the Science for Technological Innovation National Science Challenge, based at Callaghan Innovation. Willy-John's expertise brings together Māori and Indigenous perspectives with the tools of the science sector. He holds a PhD from Victoria University of Wellington for his work at the Malaghan Institute of Medical Research in Wellington. He went on to establish in Melbourne, the Walter and Eliza Hall Institute of Medical Research's first Indigenous-focussed biomedical research in its 100-year history, and was a founding member of its cultural development committee. More recently, he was the founding Deputy Chair of Rauika Māngai, a collaboration of 12 national research organisations improving the science sector interface with Māori people and Māori knowledge. He currently oversees a capability development programme delivered to 400+ researchers at 13+ research organisations across the country.



LEIGH POTTER

PGDIP HSC, NDMDI
Ngāti Porou, Ngāti Kahungunu, Rongomaiwhaine

Leigh is the Chief Operations Officer of Mātai, a not-for-profit medical research institute based in Tairāwhiti. She has more than 23 years' experience in radiology clinical practice. Leigh is an experienced imaging technologist – one of the few Māori imaging technologists in the world – and has significant leadership experience. She has an interest in supporting innovative research programmes which have strong translation into clinical practice for improving patient outcomes, especially for Māori. Leigh is a representative of the Mātai Māori Advisory Board and the National Radiology Advisory Board.

Staff directory

BOARD OF TRUSTEES

Mr Graham Malaghan | ONZM, Hon DSc (Well), FCILT – Chairman

Mr John Beattie | LLB MAICD (Well)

Mr Tim Bennett | MBA, BCom

Assoc Prof John Carter | BBiomedSc, MBChB (Otago), PhD, FAFPHM, MRNZCGP

Sir Paul Collins | KNZM, BCA, ACA

Prof Parry Guilford | MSc (Otago), PhD (CU), FRSNZ

Prof David Harper | MA, PhD (Cantab)

Mr Bryan Johnson | ONZM, BCA (Well) (to Dec 2019)

Prof Graham Le Gros | CNZM, FRSNZ, FRCPA (Hon), BSc (Massey), Dip Immunol (Otago), MPhil, PhD (Auckland)

Dr Dianne McCarthy | CNZM, CRSNZ, BA, BSc, MSc (Hons), PhD

Dr David Mossman | QSM, BVSc, MRCVS, MNZIF (to Dec 2019)

Mr Tony Mossman | BBS, DipBusStud, CA, CMinstD

Ms Nicola Sladden | LLB, MPH

Mr C Dan Williams | CA

RESEARCH & CLINICAL CONSULTANTS

Prof Bob Anderson | Immunologist and Gastroenterologist

Dr Russell Barker | Clinical Immunologist

Dr Scott Barker | Dermatologist

Dr Maia Brewerton | Clinical Immunologist, Allergist and Immunopathologist

Prof Richard Beasley | Physician, Director MRINZ

Dr Lisa Connor | Immunologist

Dr John Croese | Immunoparasitologist and gastroenterologist

Prof Brett Delahunt | Pathologist

Prof Jeroen Douwes | Epidemiologist

Dr Elizabeth Forbes-Blom | Immunologist

Assoc Prof Rebecca Grainger | Rheumatologist

Assoc Prof Andrew Harrison | Rheumatologist

Dr Sue Huang | Virologist

Dr Stephen Inns | Gastroenterologist

Prof Anne La Flamme | Immunologist

Dr Melanie McConnell | Molecular Biologist

Dr Alex McLellan | Immunologist

Claire Newbern | Epidemiologist

Dr Li Peng | Molecular Biologist

Prof David Ritchie | Haematologist

Dr Richard Steele | Clinical Immunologist

ADVISORS

Auditors | Deloitte

Bankers | ANZ Bank

Investments | Jarden

Solicitors | Simpson Grierson, AJ Park

TE URUNGI MĀORI

Dr Clive Aspin | Senior Specialist Advisor, Suicide Mortality Review Committee

Dr Amohia Bolton | Director of Whakauae Research for Māori Health Development

Dr Maia Brewerton | Clinical Immunologist, Allergist and Immunopathologist

Dr Lis Ellison-Loschmann | Researcher, Centre for Public Health Research

Dr Ruakere Hond | Kaiako

Dr Willy-John Martin | Capacity Development Advisor at Callaghan Innovation

Leigh Potter | Operations Manager Mātai Research

STAFF OF THE INSTITUTE 2019/20

SCIENTIFIC

DIRECTOR OF RESEARCH

Prof Graham Le Gros | CNZM, FRSNZ, FRCPA (Hon), BSc (Massey), Dip Immunol (Otago), MPhil, PhD (Auckland)

DEPUTY DIRECTOR OF RESEARCH

Prof Ian Hermans | BSc (Hons) (Otago), MSc (Otago), PhD (Well) – Hugh Dudley Morgans Fellow, Vaccine Research Programme Leader

PROGRAMME LEADERS

Prof Ian Hermans | BSc (Hons) (Otago), MSc (Otago), PhD (Well) – Hugh Dudley Morgans Fellow, Vaccine Research

Prof Mike Berridge | BSc, MSc (Hons), PhD (Auckland) – Cancer Cell Biology

Prof Franca Ronchese | PhD (Padua), Dip Microbiology – Immune Cell Biology

TEAM/GROUP LEADERS

Dr Rachel Perret | BSc (Hons), PhD (Otago) – Team Leader, CAR T-Cell Therapy

Dr Olivier Gasser | MSc (Strasbourg), PhD (Basel) – Group Leader, Translational Immunology

Dr Robert Weinkove | MA (Cantab), MBBS (Hons), PhD, FRACP, FRCP – Clinical Director, CAR T-cell Therapy

RESEARCH STAFF

Reigh Aguinaldo | MSc – Animal Technician (Training Specialist), BRU

Bethany Andrews | BMus (Hons) (Cardiff) – Manager, GMP

Astrid Authier-Hall | BSc MSc (Massey) – Senior Research Officer, Cancer Immunotherapy, VAANZ (part-time)

Evelyn Bauer | NZCSc, Cert Animal Sci & Tech (Massey) – Production Manager, GMP (to May 2020)

Prof Antony Braithwaite | BSc, MSc (Auckland), PhD (ANU) – Visiting Researcher

Dr Olivia Burn | BSc (Hons) (Otago), PhD (Otago) – PhD Student, Cancer Immunotherapy

Mali Camberis | BSc (Well), PGCertMS (Well) – Project Leader: Hookworm Therapy / Head of Laboratories, Allergic and Parasitic Diseases

Dr Alissa Cait | BSc, PhD (Canada) – Postdoctoral Research Fellow, Translational Immunology

Jodie Chandler | BBiomedSc (Hons) (Well) – PhD Student, Allergic and Parasitic Diseases

Sally Chappell | BSc (Hons) (Liverpool) – Senior Staff Scientist (Cell Sorting Specialist), HGCC

Dr Nathaniel Dasyam | BBiomedSc, PhD (Well), Rotary Club of Port Nicholson Ian Paterson Fellow – Postdoctoral Research Fellow, CAR T-Cell Therapy

Rebecca Dawson | BSc (Hons) (Otago) – PhD Student, Cancer Cell Biology

Regina Duffield | BBiomedSc (Melb) – Production Technician, GMP

Brian Duffy | BSc, GDipSc, PGCertSc (Well) – Technical Cleaner, BRU

Dr David Eccles | BBiomedSc (Hons) (Well), BSc (Well), PhD (Well) – Staff Scientist (Bioinformatics Analyst), HGCC

Julia Eloff | BSc (UNISA), GDipSc (Well), MSc (SUN) – Animal Technician (Animal Welfare Specialist), BRU

Marie-Sophie Fabre | BASc (UPS), BSc (UPMC), MSc Biotech (UDS) – Senior Research Officer, Immune Cell Biology

Kathryn Farrand | MSc (Massey) – Senior Research Officer, Cancer Immunotherapy (part-time)

Lewis Forsyth | BSc (Otago), Animal Technician (Genetic Quality Specialist), BRU

Dr Laura Ferrer-Font | BSc, MSc, PhD (Barcelona) – Senior Scientist (High Dimensional Spectral Cytometry Specialist), HGCC

Dr Regan Fu | BSc, MSc, PhD (Auckland) – Postdoctoral Research Fellow, Cancer Immunotherapy

Katie Gell | BBiomedSc, MCLinIm (Well) – Practicum Student/Research Officer, Translational Immunology

Dr Philip George | BSc (Hons) (Bristol), MSc, MBChB (Warwick), MRCP (London), MCLinRes, FRCPATH – Clinical Fellow, CAR T-Cell Therapy

Dr Giulia Giunti | PhD (King's College), MSc (University of Milano-Bicocca), BSc (Milano-Bicocca) – Quality Manager, GMP (part-time)

Carole Grasso | BSc (Hons) (UWE) – Research Manager, Cancer Cell Biology (to Feb 2020)

Phoebe Harnos | BSc, MDDD (Well) – Research Officer, Cancer Immunotherapy (to Nov 2019)

Amber Harris-Little | BSc (Well) – Animal Technologist, BRU

Assoc Prof Patries Herst | PhD, MPhil, MSc – Senior Research Fellow, Cancer Cell Biology (part-time)

James Hedley | Travel & Tourism – Animal Technician, BRU

Dr Kerry Hilligan | BBiomedSc, MBMedSc (Hons) (Well), PhD (Otago) – International Research Fellow, Immune Cell Biology

Evelyn Hyde | MSc (Otago) – Senior Research Officer, Immune Cell Biology

Ellie-May Jarvis | BBiomedSc (Hons) (Otago) – PhD Student, CAR T-Cell Therapy

Angela Jones | MSc (KCL), BSc (Hons) (Sunderland) – Senior Research Officer, Translational Immunology (to Aug 2019)

Jaskirat Kaur | MSc (Punjabi) – Animal Technician (Surgical Techniques Specialist), BRU

Brittany Koning | BSc (Massey), DVN (Wintec) – Animal Technician (Surgical Techniques Specialist), BRU

Dr Olivier Lamiable | PhD (Orleans) – Senior Research Fellow, Immune Cell Biology

Dr Joshua Lange | BSc (Hons) (Otago), PhD (Otago) – Postdoctoral Research Fellow, Cancer Immunotherapy

Abbie Larson | BBiomedSc (Hons) (Otago) – Research Officer, Immune Cell Biology

Brittany Lewer | BBiomedSc, MBmedSc (Well) – Research Officer, Hookworm Therapy

Yanyan Li | MBMedSc (Immunol) (Well) PGDip Biomed Science, BBiot (Shanghai Fisheries) – Research Officer, Translational Immunology

Tafeuni Mafile'o | BBiomedSc (Well) – Animal Technician (Assisted Reproductive Tech), BRU

John Mamum | BBiomedSc (Well) – MSc Student, Hookworm Therapy

Tom Marsland | BSc (Hons) (Otago) – Research Officer, Immune Cell Biology (to Feb 2020)

Dr Luis Munoz-Erazo | PhD (USyd) – Research Fellow, Immune Cell Biology

Dr Johannes Mayer | BSc, MRes, PhD (Glasgow) – Postdoctoral Research Fellow, Immune Cell Biology

Palak Mehta | BBiomedSc (Well) – Research Officer, Hookworm Therapy (to Jan 2020)

Dr Brigitta Mester | MSc (Hungary), PhD (Well) – Production Manager, GMP

Anna Mooney | BBiomedSc, MBIomedSc (Well) – Research Officer, Cancer Immunotherapy

Sophia-Louise Noble | BSc (Hons) (Well) – Research Officer, Hookworm Therapy

Yasmin Nouri | BBiomedSc (Well), MSc (Otago) – PhD student, CAR T-Cell Therapy

Hannah O'Connor | BSc, Summer Student, Allergic and Parasitic Diseases (to Jan 2020)

Dr David O'Sullivan | BA, BSc (Otago) BSc (Hons) (Well), PhD (Well) – Senior Research Fellow, Translational Immunology

Sam Old | BSc (Otago), MSc (Bioinformatics) (Melb) – Bioinformatics Research Officer, Allergic and Parasitic Diseases

Tess Ostapowicz | Research Nurse

Olga Palmer | BSc, MSc – Research Officer, Cancer Immunotherapy

Dr Christophe Pellefigues | PhD (Paris)
– Postdoctoral Research Fellow, Allergic
and Parasitic Diseases (to Sept 2019)

Dr Kef Prasit | BA Psychology (British
Columbia), PhD student (to Oct 2019),
Cancer Immunotherapy

Kylie Price | BSc (Otago), MSc (Hons)
(Well) – Head of Research Technology,
HGCC

Melanie Prout | BSc (Hons) (Well) – Senior
Research Officer, Allergic and Parasitic
Diseases

Ian Saldanha | BSc, PGDipSci (Otago),
DipVetNursing (Otago Polytech) – Head of
BRU

Alfonso Schmidt | BSc (Chile) – Senior
Staff Scientist (Bio-imaging Specialist),
HGCC

Dr Elizna Schoeman | PhD, Postdoctoral
Research Fellow, Translational Immunology
(to Sept 2019)

Sonali Sharma | BSc (Hons) (HPU), MSc
(SUBMS) – Animal Technician
(Biosecurity), BRU

Sam Small | BBiomedSc, MCLinIm (Well)
– Staff Scientist, HGCC

Luise Staatsmann | Casual, BRU

Adam Stewart | BSc (Well) – BRU Deputy
Manager / Business Analyst

Ching Wen Tang | MSc (Otago) – Senior
Research Officer, Cancer Immunotherapy

Shiau Choot Tang | Grad Dip Sci (Well)
– Senior Research Officer and Hazardous
Substances Manager, Immune Cell Biology

Dr Jeffry Tang | PhD (Auckland) –
Postdoctoral Research Fellow, Translational
Immunology

Eriuti Tanirau | Technical Cleaner, BRU

Dr Francesco Vacca | BSc (Cagliari), MSc
(Edinburgh), PhD (Edinburgh) –
Postdoctoral Research Fellow, Allergic and
Parasitic Diseases

Hannah Van Der Woude | BSc (Waikato),
BBioMedSc (Hons) – Visiting Researcher,
Translational Immunology

Sventja von Daake | MSc – Staff Scientist
(Cytomics Specialist), HGCC

Kirsty Wakelin | BBiomedSc (Hons)
(Otago) – Production Technician, GMP

Xiaodong Wang | Dip Med Tech, Dip
Midwifery (Shanxi) – Senior Animal
Technician, BRU

Greta Webb | BSc (Auckland), BBiomedSc
(Hons) (Auckland) – PhD student,
Immune Cell Biology

Dr Charlotte Williams | BCom, BVSc –
Casual Research Officer, Hookworm
Therapy

Michael Wilson | BBiomedSc (Otago),
BBiomedSc (Hons) (Well) – Research
Officer, Cancer Immunotherapy

Dr Katherine Woods | BA (Mod) Microbiol,
PhD (Dublin) – Senior Research Fellow,
Translational Immunology (to April 2020)

Jarem Wylie | BSc – PhD Student, Cancer
Immunotherapy

Dr Jianping (Mark) Yang | BM (Shanxi)
– Senior Research Officer and Regulatory
Affairs Manager, Immune Cell Biology

Brigitte Young | BBiomedSc (Well) –
Animal Technician (Genetic Quality
Specialist), BRU (to Feb 2020)

Bibek Yumnam | MSc (India) – Research
Officer, Hookworm Therapy

SUPPORT AND ADMINISTRATION

Marie Armstrong | BAP, PGDipIM (Well)
– Head of IT

Hamish Cameron | BSc (Tech) Biotech
(Waikato) – Science Communicator

Robbie Carmichael | BDI (Well), Dip Dig
Film (SAE) – Research Office
Administrator (part-time)

Lee Chappell | Office and Procurement
Coordinator

Bethany Chesser | BA (UK) – Fundraising
Administrator

Sally Culbert | BBS – Finance (Massey)
– Management Accountant (part-time)

Tim Dallas | AFMANZ – Deputy Facilities
Manager

Dr Neil Domigan | PhD, MBA, DipSci,
BPhEd, BSc – Commercial Manager: Cell
Therapies

Kira Garbe | BSc, MSc (MolBiotech)
(Heidelberg) – Business Development
Officer

Oliver Jarvis | BSc, MPE – Business
Development Officer (to Jul 2020),
Programme Manager, VAANZ (from Jul
2020)

Hannah Johnstone | BPsych (Hons) (JCU)
– HR Administrator (part-time)

Gay Keast | Operations Manager,
Development (to Nov 2019)

David Lin | CA (NZICA), MBA (Well), MAF
(Well) – Head of Finance

Yvonne Mackie | Funding Administrator
(to Dec 2019)

Gail Marshall | BA, GDip (Well) – Head of
Communications (part-time)

Heike Menne-Spohr | MCom (Well),
BCom (Hons) (UNISA) – Head of HR and
Research Office

Emma Morris | BSc (Auckland) – Health
and Safety Coordinator

Noriko Murakami | BA (Tokyo) –
Development Administration Manager

Nicola Olson | CA (NZICA), BCA (Well),
BA (Well) – Financial Accountant
(part-time)

Pat Paiti | BA, BCA (Well) – IT Support
Technician

Isla Perry | MSc (Hons) (Nottingham) –
Fundraising Events and Engagement
Advisor (to March 2020)

Lene Petersen | Accounts Payable
(part-time)

Ilse Potes Morales | BMktg & Advertising
(San Martin) – EA to Director, General
Manager and Clinical Director

Megan Riley | BA (Psych) – Fundraising
Events and Engagement Advisor

Jenny Sim | Head of Development

Darrell Smith | GCertBMgt (Well),
GDipBMgt (Well), BSc (Hons) (Well), MSc
(Well), GDipOHS (Massey), BAppSc
(Massey) – Head of Facilities (part-time)


Gaia Smith | General Duties (casual)

Jo Timewell | Facilities Assistant
(part-time)

Apii Ulberg | Cleaner

Mike Zablocki | BA (Hons) (Bristol),
PGDipBA (Well) – General Manager

Jesse Zhou | BCS (China) – Systems
Administrator





MALAGHAN
INSTITUTE
OF MEDICAL RESEARCH

info@malaghan.org.nz
www.malaghan.org.nz
+64 4 499 6914

 MalaghanInstitute
 Malaghan_Inst

Charity Reg: CC10357

Victoria University
Gate 7, Kelburn Pde
PO Box 7060
Wellington 6242
New Zealand